Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report
Toni T. Seppälä(University of Helsinki), Aysel Ahadova(Heidelberg University), Mev Dominguez–Valentin(Oslo University Hospital), Finlay Macrae(The Royal Melbourne Hospital), D. Gareth Evans(University of Manchester), Christina Therkildsen(Copenhagen University Hospital), Julian R. Sampson(Cardiff University), Rodney J. Scott(Hunter Medical Research Institute), John Burn(Newcastle University), Gabriela Möslein(Witten/Herdecke University), Inge Bernstein(Aalborg University Hospital), Elke Holinski‐Feder(LMU Klinikum), Kirsi Pylvänäinen(Central Finland Health Care District), Laura Renkonen‐Sinisalo(Helsinki University Hospital), Anna Lepistö(Helsinki University Hospital), Charlotte Kvist Lautrup(Aalborg University Hospital), Annika Lindblom(Karolinska Institutet), John‐Paul Plazzer(The Royal Melbourne Hospital), Ingrid Winship(The Royal Melbourne Hospital), Douglas Tjandra(The Royal Melbourne Hospital), Lior H. Katz(Sheba Medical Center), Stefan Aretz(University of Bonn), Robert Hüneburg(University Hospital Bonn), Stefanie Holzapfel(University Hospital Bonn), Karl Heinimann(University Hospital of Basel), Adriana Della Valle(Hospital Central de las Fuerzas Armadas), Florencia Neffa(Hospital Central de las Fuerzas Armadas), Nathan Gluck(Tel Aviv Sourasky Medical Center), Wouter H. de Vos tot Nederveen Cappel(Isala), Hans F. A. Vasen(Leiden University), Monika Morak(LMU Klinikum), Verena Steinke‐Lange(LMU Klinikum), Christoph Engel(Leipzig University), Nils Rahner(Heinrich Heine University Düsseldorf), Wolff Schmiegel(Universitätsklinikum Knappschaftskrankenhaus Bochum), Deepak Vangala(Universitätsklinikum Knappschaftskrankenhaus Bochum), Huw Thomas(St. Mark's Hospital), Kate Green(University of Manchester), Fiona Lalloo(University of Manchester), Emma J. Crosbie(University of Manchester), James Hill(University of Manchester), Gabriel Capellá(Institut d'Investigació Biomédica de Bellvitge), Marta Pineda(Institut d'Investigació Biomédica de Bellvitge), Matilde Navarro(Institut d'Investigació Biomédica de Bellvitge), Ignacio Blanco(Institut d'Investigació Biomédica de Bellvitge), Sanne W. ten Broeke(University Medical Center Groningen), Maartje Nielsen(Leiden University), Ken Ljungmann(Aarhus University Hospital), Sigve Nakken(Oslo University Hospital), Noralane M. Lindor(Mayo Clinic in Arizona), Ian M. Frayling(Cardiff University), Eivind Hovig(University of Oslo), Lone Sunde(Aarhus University Hospital), Matthias Kloor(Heidelberg University), Jukka‐Pekka Mecklin(Central Finland Health Care District), Mette Kalager(Massachusetts Department of Public Health), Pål Møller(Oslo University Hospital)
Cited by 63Open Access
Abstract
BACKGROUND: carriers, provided the screening interval is sufficiently short and colonoscopic practice is optimal. METHODS: carriers were recruited for prospective surveillance by colonoscopy. Only variants scored by the InSiGHT Variant Interpretation Committee as class 4 and 5 (clinically actionable) were included. CRCs detected at the first planned colonoscopy, or within one year of this, were excluded as prevalent cancers. RESULTS: = 0.14). CONCLUSIONS: carriers.
Related Papers
No related papers found
Powered by citation graph analysis